High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
about
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutationOptimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settingsEvaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samplesMinority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratoriesMechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excisionGenotypic testing for human immunodeficiency virus type 1 drug resistance.Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assaysEvolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapySensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisQuality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.The Brazilian network for HIV-1 genotyping external quality control assurance programme.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donorsPersistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation.Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyHIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes.Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceReverse transcriptase and protease sequence evolution in two HIV-1-infected couples.Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assayHIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mLHIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences.N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.Use of a novel virus inactivation method for a multicenter avian influenza real-time reverse transcriptase-polymerase chain reaction proficiency study.
P2860
Q28474274-0E502349-7F4F-44ED-BC03-AE4FBE70F827Q28478154-C4831963-80D6-4697-92D1-8900C8D7CF38Q28539725-9D1B391D-9319-49B6-ACBB-15D0774D3B26Q33601530-3D9EAF3A-8FE6-464E-B298-548C7416FDB4Q33812743-B22F4CF2-591C-404F-8B80-3F462501DB74Q33824827-6D830E36-25EA-4B2E-A691-A19AD5E23581Q33836938-FB6D0BC3-44F1-4870-84BD-77F9D3BE48B6Q33906239-8C990347-D4F5-4E1B-A531-2B62F04E409FQ34041819-D94AF232-2292-40C7-A2F5-C872CBDB9F75Q34106209-15E9E9E0-EF3C-4574-AE80-049EEB70C610Q34143613-1EC9D64E-45CD-47B4-AE22-6B36FA4A585CQ34528801-A1C74EEE-2407-468C-BAC4-57EBA3E418D8Q34746064-0B70D624-D016-4D69-A7B5-3493DC36A89BQ35156231-567EC128-BCAD-4B9D-B6AF-3CC0FA154CACQ35300021-709D09E8-E3B8-4B28-80AB-5CA274249F21Q35338638-38B4CF14-A7CD-4DBD-AEBA-65925A06AB09Q35742512-812846D4-D77A-4807-BD72-C0E9F8478852Q35765985-4C983A55-5494-4E8C-8741-71205BF6C29EQ36246775-132CDCC8-81CA-42E4-A7CB-E90068708318Q36315090-38F5EB38-169F-419C-80E0-0108A8C6B210Q36610081-E2BF14FE-83C8-41E4-B30B-3A0DC1BA448CQ36899989-FBE2652C-5EE8-4C97-B695-400DFBF0888CQ36900004-04A17C16-EFDE-4962-BE32-5E39794AD109Q36905669-72681419-D5D7-414D-98F6-D1C0931E8017Q36949610-CC2622C6-0292-4C36-A7DD-237E08D4B1CDQ37003252-132DA7D1-B4AA-4F73-A082-3D2B8AAE5753Q37066539-0CA9CFCA-5DDA-4199-B52D-D954B82C43C6Q37247555-4B3C4E60-29C3-48F5-AA6B-E73106366FFCQ38738833-97C97F60-7010-42EA-8C77-B5EF2D117BBBQ40769991-8490238A-F755-4EB6-9136-055342D5CB29Q40909665-1FF7FC96-3F1C-4074-A02F-A59C6B04D173Q41835134-0CC4DAED-403D-4AAE-A2BB-6971975DEB7FQ42133979-6B6663E4-0D92-40B7-9E22-635D833E4759Q42196037-31682AB6-730F-4C11-8F97-6A4856BDFCEEQ43105557-1E551A83-74F2-4239-BE67-D22259E01EDAQ43250924-2C0B2701-D2E4-4C64-BE61-E867A68D83ABQ45515515-F2275B72-60D2-4834-87C0-512BDF90B71B
P2860
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
High degree of interlaboratory ...... from heavily treated patients
@en
High degree of interlaboratory ...... from heavily treated patients.
@nl
type
label
High degree of interlaboratory ...... from heavily treated patients
@en
High degree of interlaboratory ...... from heavily treated patients.
@nl
prefLabel
High degree of interlaboratory ...... from heavily treated patients
@en
High degree of interlaboratory ...... from heavily treated patients.
@nl
P2093
P2860
P1476
High degree of interlaboratory ...... from heavily treated patients
@en
P2093
A R Zolopa
B A Larder
R Harrigan
R W Shafer
T C Merigan
P2860
P304
P356
10.1128/JCM.39.4.1522-1529.2001
P407
P577
2001-04-01T00:00:00Z